ATE427494T1 - Verfahren zur quantifizierung der akt-protein- expression - Google Patents

Verfahren zur quantifizierung der akt-protein- expression

Info

Publication number
ATE427494T1
ATE427494T1 AT01927036T AT01927036T ATE427494T1 AT E427494 T1 ATE427494 T1 AT E427494T1 AT 01927036 T AT01927036 T AT 01927036T AT 01927036 T AT01927036 T AT 01927036T AT E427494 T1 ATE427494 T1 AT E427494T1
Authority
AT
Austria
Prior art keywords
quantifying
proteins
protein expression
quantification
detection
Prior art date
Application number
AT01927036T
Other languages
English (en)
Inventor
Sarah Bacus
Andrei Gudkov
Original Assignee
Ventana Med Syst Inc
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventana Med Syst Inc, Univ Illinois filed Critical Ventana Med Syst Inc
Application granted granted Critical
Publication of ATE427494T1 publication Critical patent/ATE427494T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01927036T 2000-04-14 2001-04-16 Verfahren zur quantifizierung der akt-protein- expression ATE427494T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19778000P 2000-04-14 2000-04-14

Publications (1)

Publication Number Publication Date
ATE427494T1 true ATE427494T1 (de) 2009-04-15

Family

ID=22730734

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927036T ATE427494T1 (de) 2000-04-14 2001-04-16 Verfahren zur quantifizierung der akt-protein- expression

Country Status (9)

Country Link
US (2) US20020015974A1 (de)
EP (1) EP1301794B1 (de)
JP (1) JP4317913B2 (de)
AT (1) ATE427494T1 (de)
AU (2) AU5352901A (de)
CA (1) CA2406443C (de)
DE (1) DE60138192D1 (de)
ES (1) ES2322888T3 (de)
WO (1) WO2001079855A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218909D0 (en) * 2002-08-15 2002-09-25 Qinetiq Ltd Histological assessment
MXPA06011219A (es) 2004-03-29 2007-05-08 Univ South Florida Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
CA2626456C (en) * 2005-10-18 2018-01-09 George Mason Intellectual Properties, Inc. Mtor pathway theranostic
DK2444807T3 (da) * 2006-11-01 2014-08-11 Ventana Med Syst Inc Mono- og dinitropyrazolhaptenkonjugater
JP4795203B2 (ja) * 2006-11-13 2011-10-19 シスメックス株式会社 アンスラサイクリン系抗癌剤の感受性判定方法及びそのシステム
EP2167963B1 (de) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymerträger für immunohistochemie und in situ hybridisierung
KR101667960B1 (ko) * 2007-07-25 2016-10-20 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료에서 이용하기 위한 멀티키나아제 억제제
EP2453234B1 (de) * 2007-10-29 2014-01-15 Eisai R&D Management Co., Ltd. Verfahren zur Vorhersage der Fähigkeit einer Zearalenon-Analogverbindung zur Behandlung von Krebs
US7837125B2 (en) * 2007-12-27 2010-11-23 Apple Inc. Methods and systems for encoding a magnetic stripe
WO2009149013A2 (en) 2008-06-05 2009-12-10 Ventana Medical Systems, Inc. Compositions comprising nanomaterials and method for using such compositions for histochemical processes
US8875886B2 (en) * 2008-08-25 2014-11-04 Apple Inc. Carrier card arrangement with removable envelope

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
US5846749A (en) * 1994-10-12 1998-12-08 The Regents Of The University Of California Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination
US6218521B1 (en) * 1997-07-17 2001-04-17 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with gastric cancer and methods for diagnosing and treating gastric cancer
ATE271691T1 (de) * 2000-01-12 2004-08-15 Ventana Med Syst Inc Verfahren zum nachweis der effektivität einer krebstherapie
WO2001079557A2 (en) * 2000-04-12 2001-10-25 Agensys, Inc. Gtp-binding protein useful in treatment and detection of cancer

Also Published As

Publication number Publication date
AU2001253529B2 (en) 2006-04-27
US20050106639A1 (en) 2005-05-19
JP2004512495A (ja) 2004-04-22
EP1301794B1 (de) 2009-04-01
CA2406443A1 (en) 2001-10-25
EP1301794A2 (de) 2003-04-16
CA2406443C (en) 2009-06-23
DE60138192D1 (de) 2009-05-14
US20020015974A1 (en) 2002-02-07
ES2322888T3 (es) 2009-07-01
AU5352901A (en) 2001-10-30
WO2001079855A2 (en) 2001-10-25
JP4317913B2 (ja) 2009-08-19
WO2001079855A3 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
EP2520935A3 (de) Organspezifische Proteine und Verfahren zu deren Verwendung
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
ATE425266T1 (de) Aptamer-nanopartikelkonjugate und verwendungsverfahren zur detektion von zielanalyten
EP1447665A3 (de) Methode zur Veringerung des EInflusses von Hämatokrit auf die Analytbestimmung in Vollblut und Testkit sowie Testartikel geeignet für diese Methode
BRPI0707645B8 (pt) métodos in vitro para detecção de câncer em um indivíduo e para avaliação de prognóstico de um indivíduo tendo, ou suspeito de ter, câncer ovariano
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
DE60228557D1 (de) Candida-nachweis
DE60129151D1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
ATE427494T1 (de) Verfahren zur quantifizierung der akt-protein- expression
BR9406223A (pt) Método para determinar em uma amostra a atividade funcional de um componente da coagulação sanguinea método para diagnosticar um disturbio da coagulação/anticoagulação sanguinea preparado de anticorpo linhagem celular uso de fator v subunidades ou fragmentos do mesmo tendo atividade anticoagulante na forma de cofator par apc prepraro de plasma embalado plasma deficiente em atividade anticoagulante de fator v como cofator para apc uso do preparado de anticorpo preparado de proteina s preparado de
WO2007024735A3 (en) Method and antibodies for detecting nitrofuran
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
WO2002066982A8 (de) Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)
DE60332370D1 (de) Bakterientestverfahren mit bindung einer intrazellularer enzyme
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
DE602006015727D1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
CY1109461T1 (el) Βελτιωμενες μεθοδοι ανοσολογικου προσδιορισμου
WO2006099537A3 (en) The use of antibody-surrogate antigen systems for detection of analytes
DE60012723D1 (de) Verfahren zur bestimmung von disaccharidasen
DK1192469T3 (da) Assay
DE69920981D1 (de) Knorpelresorptionsassays
EP2407787A3 (de) Verfahren für den Nachweis von L523S-Expression in biologischen Proben
IL160531A0 (en) Compositions and methods for aa4rp assay

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1301794

Country of ref document: EP